Stocks · News reference
Dyne Therapeutics, Inc. announced that its management team is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference in London.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Dyne Therapeutics announced its financial results for the third quarter of 2026 and provided updates on its clinical programs, including the priority review status of its BLA for z-rostudirsen.
Filed: 2026-11-05 AccNo: 0001818794-26-000013 Size: 319 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Oppenheimer has downgraded Dyne Therapeutics from Outperform to Perform, setting a price target of $15.
HC Wainwright & Co. analyst Ananda Ghosh maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and lowers the price target from $50 to $32.